Efficacy and safety of ensitrelvir in patients with mild-to-moderate COVID-19: A protocol for a multicenter, randomized, double-blind, placebo-controlled, phase 3 study (the SCORPIO-SR trial)
Hiroshi Yotsuyanagi, Norio Ohmagari, Yohei Doi, Takumi Imamura, Takuhiro Sonoyama, Genki Ichihashi, Takao Sanaki, Yuko Tsuge, Takeki Uehara, Hiroshi Mukae
doi: https://doi.org/10.1101/2022.07.15.22277670
Hiroshi Yotsuyanagi
1The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
MD, PhDNorio Ohmagari
2Disease Control and Prevention Center, National Center for Global Health, Tokyo, Japan
MD, PhDYohei Doi
3Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
4Departments of Microbiology and Infectious Diseases, Fujita Health University School of Medicine, Toyoake, Japan
MD, PhDTakumi Imamura
5Drug Development and Regulatory Science Division, Shionogi & Co., Ltd., Osaka, Japan
MSTakuhiro Sonoyama
5Drug Development and Regulatory Science Division, Shionogi & Co., Ltd., Osaka, Japan
MD, PhDGenki Ichihashi
5Drug Development and Regulatory Science Division, Shionogi & Co., Ltd., Osaka, Japan
MPharmTakao Sanaki
6Pharmaceutical Research Division, Shionogi & Co., Ltd., Osaka, Japan
PhDYuko Tsuge
5Drug Development and Regulatory Science Division, Shionogi & Co., Ltd., Osaka, Japan
MSTakeki Uehara
5Drug Development and Regulatory Science Division, Shionogi & Co., Ltd., Osaka, Japan
PhDHiroshi Mukae
7Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
MD, PhD
Posted July 17, 2022.
Efficacy and safety of ensitrelvir in patients with mild-to-moderate COVID-19: A protocol for a multicenter, randomized, double-blind, placebo-controlled, phase 3 study (the SCORPIO-SR trial)
Hiroshi Yotsuyanagi, Norio Ohmagari, Yohei Doi, Takumi Imamura, Takuhiro Sonoyama, Genki Ichihashi, Takao Sanaki, Yuko Tsuge, Takeki Uehara, Hiroshi Mukae
medRxiv 2022.07.15.22277670; doi: https://doi.org/10.1101/2022.07.15.22277670
Efficacy and safety of ensitrelvir in patients with mild-to-moderate COVID-19: A protocol for a multicenter, randomized, double-blind, placebo-controlled, phase 3 study (the SCORPIO-SR trial)
Hiroshi Yotsuyanagi, Norio Ohmagari, Yohei Doi, Takumi Imamura, Takuhiro Sonoyama, Genki Ichihashi, Takao Sanaki, Yuko Tsuge, Takeki Uehara, Hiroshi Mukae
medRxiv 2022.07.15.22277670; doi: https://doi.org/10.1101/2022.07.15.22277670
Subject Area
Subject Areas
- Addiction Medicine (367)
- Allergy and Immunology (688)
- Anesthesia (184)
- Cardiovascular Medicine (2740)
- Dermatology (234)
- Emergency Medicine (412)
- Epidemiology (12386)
- Forensic Medicine (10)
- Gastroenterology (784)
- Genetic and Genomic Medicine (4252)
- Geriatric Medicine (394)
- Health Economics (699)
- Health Informatics (2749)
- Health Policy (1017)
- Hematology (369)
- HIV/AIDS (878)
- Medical Education (404)
- Medical Ethics (111)
- Nephrology (451)
- Neurology (4026)
- Nursing (216)
- Nutrition (598)
- Oncology (2122)
- Ophthalmology (604)
- Orthopedics (251)
- Otolaryngology (311)
- Pain Medicine (256)
- Palliative Medicine (77)
- Pathology (477)
- Pediatrics (1146)
- Primary Care Research (465)
- Public and Global Health (6644)
- Radiology and Imaging (1444)
- Respiratory Medicine (886)
- Rheumatology (420)
- Sports Medicine (351)
- Surgery (464)
- Toxicology (57)
- Transplantation (192)
- Urology (171)